StonvexLoading…
StonvexStonvexStonvexCore line items from CNM's most recent SEC filings (10-K / 10-Q via EDGAR XBRL). Last 4 reporting periods.
| Metric | Annual 2026 2026-02-01 | Q4 2025 2025-11-02 | Q3 2025 2025-08-03 | Q2 2025 2025-05-04 |
|---|---|---|---|---|
Revenue | $7.65B | $6.07B | $4.00B | $1.91B |
Operating Income | $722.00M | $604.00M | $384.00M | $171.00M |
Net Income | $441.00M | $371.00M | $234.00M | $100.00M |
EPS (Diluted) | $2.31 | $1.94 | $1.22 | $0.52 |
Total Assets | $6.08B | $6.30B | $6.31B | $6.28B |
Total Liabilities | $4.01B | $4.25B | $4.34B | $4.46B |
Cash & Equivalents | $220.00M | $89.00M | $25.00M | $8.00M |
Free Cash Flow OCF − CapEx | $604.00M | $351.00M | $88.00M | $64.00M |
Shares Outstanding | 197.86M | 198.30M | 198.50M | 198.70M |